Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Leukapheresis Product market volume is expected to reach USD 27.1 billion in the next 10 years with a CAGR of 7.8%. The Leukapheresis Products Market is significantly influenced by many market factors which drive the market dynamics and determine the development pathway of the market. One of the major factors fuelling the growth of this market has been the increased prevalence of leukemia and other blood related illnesses. With population growing rapidly and aging at the same time, the occurrence of such diseases has significantly increased compared to before, making advanced therapeutic interventions like leukapheresis necessary. Additionally, the rising awareness and early diagnosis of blood disorders contribute greatly to the upsurge of demand for leukapheresis products.
Technology is one of the main factors that influence the development of the market environment. The leukapheresis products keep on innovating, which has resulted in the manufacture of more efficacious and user friendly devices, and hence, better patient experience and treatment outcomes. The incorporation of automation and development of advanced devices has not only increased the effectiveness of leukapheresis procedures but at the same time has made the healthcare streamline, which has led to the market expansion.
Another key element influencing the Leukapheresis Products Industry involves the regulatory environment. Strict regulatory frameworks and compliance standards dictated by health authorities worldwide shape the regulation and marketing of such products. Manufacturers in the leukapheresis industry need to comply with the strictest rules of the regulatory authorities in order to guarantee the safety and efficacy of their products before entering the market. These regulations are at the same time a challenge and an opportunity, as companies that manage the compliance environment will gain a competitive edge.
The rivalry and participation of key actors has a profound impact on the structure of the leukapheresis market. The existing companies with greatly established market share and participation of new entrants and startups trigger competition and innovation. Collaborations, partnerships and mergers within the industry are the strategies used by companies to strengthen their market position and expand their product line.
Also, regional economic structures and healthcare expenditure help the leukapheresis products market expand. Developed nations with strong medical facilities as a rule follow the trend for higher adoption rates of the advanced medical technology, including leukapheresis products. On the other hand, the speed of uptake might be restricted for developing countries because of the financial issues and limited healthcare resources they have at their disposal. Markets players mostly adapt their strategies depending on the regional economic conditions seeking to take advantage of growing opportunities.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Growth Rate | Â Â 7.8% (2023-2032) |
Leukapheresis Products Market Highlights:
Global Leukapheresis Products Market Overview
Leukapheresis products market is expected to reach USD 27.1 million at a CAGR 7.8% during the forecast period 2023-2032. Leukapheresis is a blood therapy that removes aberrant white blood cells (WBCs).
Leukemia can be treated using leukapheresis, or it can be utilized as the initial stage in CAR T-cell therapy. The rising number of blood donors, the rising prevalence of leukemia, and the demand for leukapheresis products in clinical trials are all expected to drive the market forward. The high cost of therapeutic leukapheresis, a scarcity of qualified experts, and strict donor recruitment requirements, on the other hand, may limit market expansion over the projection period. Despite its therapeutic potential, leukapheresis is currently a rare treatment option, especially for hyperleukocytosis leukemia.
January 2023: Sanguine Biosciences, a pioneer in the connection of patients with biopharmaceutical companies to expedite precision medicine R&D and Cell & Gene Therapy, today announced a new investment from BroadOak Capital Partners, LLC, a prominent direct investment and advisory firm that specializes in life science research tools, pharmaceutical services, and diagnostics. Sanguine's laboratory operations, leukapheresis offerings, and patient donor network are all enhanced by the partnership with BroadOak.
Sanguine introduced a new apheresis product family in October 2022, which offers researchers a substantial quantity of immune and hematopoietic stem cells from single donors with confirmed disease. The offering addresses a significant unmet need in the field of life science research and development, with a particular emphasis on the high-growth and high-impact cell and gene therapy sector. Biopharmaceutical researchers employ human biospecimens for biomarker development, which can result in innovative clinical applications as a result of the translation of bench discoveries into bedside treatments for patients.
However, the procurement and processing of pertinent patient samples for research purposes are complicated by the complexity of biologic- and cell-based therapies. Through partnerships with patient advocacy groups and a comprehensive recruitment apparatus, Sanguine Biosciences simplifies this process and provides researchers with access to a diverse, nationwide network of over 60,000 patient donors.
February 2021: Lonza has expanded its renowned human primary cell offerings with the introduction of high-quality cryopreserved Leukopaks that are entirely customizable. Leukopaks that are frozen will facilitate the long-distance shipment of leukapheresis products without the potential for diminished cell viability that is a concern with fresh Leukopaks. The cryopreserved Leukopaks are designed for long-term storage in research laboratories, and they also provide immediate access to viable cells, thereby enhancing workflow flexibility and convenience. The cryopreserved Leukopaks are available in a variety of sizes, and a distinctive costing structure enables customers to only pay for the customization that is required.
Additionally, customers have access to a variety of donor characteristics and testing options. A Leukopak is a product that is enriched through leukapheresis and contains high concentrations of peripheral blood mononuclear cells, including T cells, B cells, and monocytes. Before progressing to full clinical manufacturing, these cells are a critical raw material in immunotherapy research and for optimizing the development of the cell therapy process. Nevertheless, it can be challenging to obtain fresh Leukopaks and they must be used promptly to prevent cell degradation.
Therapeutic leukapheresis in the treatment of pediatric patients, on the other hand, is becoming a hot topic among industry participants. This is primarily due to the negative effects and hazards of traditional treatments for children, such as chemotherapy. Leukapheresis can be used to treat or remove excess WBCs in children with lymphoma, as well as to collect stem cells from children for other cancer patients. The possibilities and benefits of leukapheresis in this application make it a market focus, especially as only a few hospitals in both developed and emerging economies presently provide leukapheresis treatment for children.
Leukapheresis Products Market Segment Insights
The leukapheresis products market has been segmented into type, application, and end user.
Leukapheresis Products Type Insights
On the basis of type, the market has been segmented into leukapheresis devices and leukapheresis disposables. The leukapheresis devices segment has been segmented into apheresis devices, leukapheresis column & cell separators, and leukoreduction filters.
Leukapheresis Products Application Insights
The market, on the basis of application, has been segmented into research applications and therapeutic applications.
Leukapheresis Products End User Insights
On the basis of end user, the market has been segmented into blood component providers and blood centers, hospitals and transfusion centers, and others.
Leukapheresis Products Regional Insights
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The leukapheresis products market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European leukapheresis products market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The leukapheresis products market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The leukapheresis products market in the Middle East & Africa has been segmented into the Middle East and Africa.
Leukapheresis Products Market Top Key Players
some of the key players in the leukapheresis products market are
- Haemonetics
- Terumo BCT
- Asahi Kasei Medical
- STEMCELL Technologies
- Macopharma
- HemaCare Corporation
- Caltag Medsystem
- ALLCells LLC
- ZENBIO
- Fresenius Kabi
- PPA Research Group
- StemExpress
Regional Market Summary
Geographically, the Americas is anticipated to dominate the leukapheresis products market owing to the growing number of blood donations, rising incidence and prevalence of leukaemia and growing demand for leukopaks in clinical research. According to the America’s Blood Centers, more than 15 million pints of blood are transfused in the US each year.
Europe is expected to hold the second largest position in the leukapheresis products market. The market growth in this region is attributed to the increasing prevalence of leukemia and well-developed healthcare sector in the region. According to the Cancer Research UK, about 9,900 new cases of leukaemia were reported in UK in 2015.
The leukapheresis products market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increase in regenerative medicine research in the region, growth in the number of clinical trials for CAR-T therapy, and the increasing presence of major multinational pharma and biotech companies, and improvement in healthcare access.
The Middle East & Africa has the lowest share of the leukapheresis products market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.
Recent Development
Cryoport Inc. and Cell Matters SA formed a strategic agreement in February 2022 to provide end-to-end cryopreservation services for leukapheresis-derived therapies in the life sciences industry, enabling both autologous and allogeneic cell therapies. Terumo Blood and Cell Technologies revealed in July 2021 that physicians would be able to perform extracorporeal photopheresis immunotherapy (ECP) operations at the patient's bedside. Spectra Optia's functionality has been enhanced by the firm. These devices can now be used to perform the UVA PIT System ECP as a functionally closed, online, multistep system using mononuclear cell collection (MNC) and continuous mononuclear cell collection (CMNC) protocols.
Leukapheresis Products Market Segmentation
Leukapheresis Products Type Outlook
- Leukapheresis Devices
- Apheresis Devices
- Leukapheresis Columns & Cell Separators
- Leukoreduction Filters
- Leukapheresis Disposables
Leukapheresis Products Application Outlook
- Research Applications
- Therapeutic Applications
Leukapheresis Products End User Outlook
- Blood Component Providers and Blood Centers
- Hospitals and Transfusion Centers
- Others
Leukapheresis Products Regional Outlook
- Americas
- North America
- US
- Canada
- South America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- The Middle East & Africa
- Middle East
- Africa
Intended Audience
- Apheresis Device Manufacturers and Distributors
- Leukapheresis Product Manufacturers and Distributors
- Pharmaceutical and Biotechnological Companies
- Healthcare Service Providers (including Hospitals and Transfusion Centers)
- Cancer Treatment Centers
- Blood Component Providers & Blood Centers
- Contract Research Organizations
- Academic and Research Institutes
- Government Associations
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
